The clinical significance of ASS1 expression has been investigated in several types of human tumors, including endometrial cancer [100], breast cancer [101], myxofibrosarcoma [102], and bladder cancer [103], in which ASS1 deficiency or low ASS1 expression has been associated with a poor prognosis or enhanced invasive capability. This evidence concerns the gene ASS1 and urinary bladder cancer.